Dabrafenib and its potential for the treatment of metastatic melanoma
The purpose of this study is to review the development of BRAF inhibitors, with emphasis on the trials conducted with dabrafenib (GSK2118436) and the evolving role of dabrafenib in treatment for melanoma patients. Fifty percent of cutaneous melanomas have mutations in BRAF, resulting in elevated act...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523565/ |